Ethics and equity in access to disease‐modifying therapies and newborn screening for spinal muscular atrophy: A scoping review

Documenti analoghi

• Cognitive and neurodevelopmental disorders in spinal muscular atrophy type I at the time of disease‐modifying therapies
  di: Giorgia Coratti, et al.
  Pubblicazione: (2025)
• Cerebral palsy in African paediatric populations: A scoping review
  di: Serini Murugasen, et al.
  Pubblicazione: (2024)
• Bulbar function in children with spinal muscular atrophy type 1 treated with nusinersen
  di: Georgia Stimpson, et al.
  Pubblicazione: (2025)
• Challenges in assessing autism spectrum disorder in spinal muscular atrophy type 1
  di: Bianca Buchignani, et al.
  Pubblicazione: (2026)
• Expressive language and social communication abilities in children with spinal muscular atrophy type 1
  di: Chiara Brusa, et al.
  Pubblicazione: (2025)